AFEYAN NOUBAR
20 insider transactions on file
All transactions
| Date | Ticker | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-05-21 | MRNA | Moderna, Inc. | Sale | 9,263 | $46.84 | $433,878.92 | filing |
| 2026-05-21 | MRNA | Moderna, Inc. | Option exercise | 9,263 | $19.15 | $177,386.45 | filing |
| 2026-03-02 | GENB | Generate Biomedicines, Inc. | Buy | 1,562,500 | $16.00 | $25.0M | filing |
| 2026-03-02 | GENB | Generate Biomedicines, Inc. | Buy | 1,562,500 | $16.00 | $25.0M | filing |
| 2026-03-02 | GENB | Generate Biomedicines, Inc. | Buy | 1,562,500 | $16.00 | $25.0M | filing |
| 2026-03-02 | GENB | Generate Biomedicines, Inc. | Buy | 1,562,500 | $16.00 | $25.0M | filing |
| 2026-03-02 | GENB | Generate Biomedicines, Inc. | Buy | 1,562,500 | $16.00 | $25.0M | filing |
| 2026-03-02 | GENB | Generate Biomedicines, Inc. | Buy | 1,562,500 | $16.00 | $25.0M | filing |
| 2026-03-02 | GENB | Generate Biomedicines, Inc. | C | 2,777,752 | — | — | filing |
| 2026-03-02 | GENB | Generate Biomedicines, Inc. | C | 2,777,752 | — | — | filing |
| 2026-03-02 | GENB | Generate Biomedicines, Inc. | C | 12,723,940 | — | — | filing |
| 2026-03-02 | GENB | Generate Biomedicines, Inc. | C | 12,723,940 | — | — | filing |
| 2026-03-02 | GENB | Generate Biomedicines, Inc. | C | 13,702,224 | — | — | filing |
| 2026-03-02 | GENB | Generate Biomedicines, Inc. | C | 987,491 | — | — | filing |
| 2026-03-02 | GENB | Generate Biomedicines, Inc. | C | 2,777,752 | — | — | filing |
| 2026-03-02 | GENB | Generate Biomedicines, Inc. | C | 2,777,752 | — | — | filing |
| 2026-03-02 | GENB | Generate Biomedicines, Inc. | C | 13,702,224 | — | — | filing |
| 2026-03-02 | GENB | Generate Biomedicines, Inc. | C | 987,491 | — | — | filing |
| 2025-12-11 | MRNA | Moderna, Inc. | Sale | 23,853 | $29.49 | $703,305.71 | filing |
| 2025-12-11 | MRNA | Moderna, Inc. | Option exercise | 23,853 | $10.90 | $259,997.70 | filing |
Insider transactions from SEC Form 4 filings via EDGAR. Names appear as filed and aren't normalized across issuers.